10 October 2025
10 October 2025
Novo鈥檚 acquisition of FGF21 drug developer Akero follows similar deals by Roche and GSK earlier in 2025.
MFN-driven drug price reductions are unlikely to impact pharma R&D spending.
The API production site is AstraZeneca鈥檚 largest investment into in the state of Virginia to date.
The 2025/26 flu season sees pharma companies shift to trivalent vaccines based on WHO recommendations.
Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron Pharmaceuticals and Bayer.
The partnership will leverage Turbine鈥檚 platform and its capacity to streamline the ADC discovery process.
Analysts forecast that the drug will quickly obtain market share from the current SoC drugs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
